ESR1 and breast carcinoma: Aromatase inhibitors (AIs) such as the non-steroidal Anastrozole (Ana), Letrozole (Let), and steroidal Exemestane (Exe) are selective estrogen receptor down-regulators and considered the first-line hormone therapy in postmenopausal patients with breast cancer (68).